Royalty Pharma plc Proceeds from Equity Method Investment, Distribution, Return of Capital
Royalty Pharma plc (RPRX) reported Proceeds from Equity Method Investment, Distribution, Return of Capital of $29.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital · last filed 2026-08-05
- Royalty Pharma plc proceeds from equity method investment, distribution, return of capital for the quarter ending 2026-06-30 was -$13.21M, a 120.98% decline year-over-year.
- Royalty Pharma plc proceeds from equity method investment, distribution, return of capital for the quarter ending 2026-03-31 was $42.31M, a 16.67% increase year-over-year.
- Royalty Pharma plc proceeds from equity method investment, distribution, return of capital for the quarter ending 2025-12-31 was $4.99M, a 53.95% increase year-over-year.
- Royalty Pharma plc proceeds from equity method investment, distribution, return of capital for the quarter ending 2025-09-30 was $905.00K, a 92.12% decline year-over-year.
- Royalty Pharma plc proceeds from equity method investment, distribution, return of capital for fiscal 2025 was $105.15M, a 344.77% increase from fiscal 2024.
- Royalty Pharma plc proceeds from equity method investment, distribution, return of capital for fiscal 2024 was $23.64M, a 46.13% decline from fiscal 2023.
- Royalty Pharma plc proceeds from equity method investment, distribution, return of capital for fiscal 2023 was $43.88M.
- Royalty Pharma plc proceeds from equity method investment, distribution, return of capital for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Equity Method Investment, Distribution, Return of Capital 3 month | Proceeds from Equity Method Investment, Distribution, Return of Capital 6 month | Proceeds from Equity Method Investment, Distribution, Return of Capital 9 month | Proceeds from Equity Method Investment, Distribution, Return of Capital 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $29.09M 10-Q · filed 2026-08-05 | $34.09M derived: sum of 3 quarters · filed 2026-08-05 | $34.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $42.31M 10-Q · filed 2026-05-06 | $47.30M derived: sum of 2 quarters · filed 2026-05-06 | $48.20M derived: sum of 3 quarters · filed 2026-05-06 | $111.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $5.90M derived: sum of 2 quarters · filed 2026-02-11 | $68.89M derived: sum of 3 quarters · filed 2026-08-05 | $105.15M 10-K · filed 2026-02-11 |
| 2025-09-30 | $905.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $63.89M derived: sum of 2 quarters · filed 2026-08-05 | $100.16M 10-Q · filed 2025-11-05 | $103.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $62.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $99.25M 10-Q · filed 2026-08-05 | $102.49M derived: sum of 3 quarters · filed 2026-08-05 | $113.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $36.26M 10-Q · filed 2026-05-06 | $39.51M derived: sum of 2 quarters · filed 2026-05-06 | $50.99M derived: sum of 3 quarters · filed 2026-05-06 | $54.94M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $14.73M derived: sum of 2 quarters · filed 2026-02-11 | $18.68M derived: sum of 3 quarters · filed 2026-02-11 | $23.64M 10-K · filed 2026-02-11 |
| 2024-09-30 | $11.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $15.43M derived: sum of 2 quarters · filed 2025-11-05 | $20.40M 10-Q · filed 2025-11-05 | $25.05M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $3.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $8.91M 10-Q · filed 2025-08-06 | $13.56M derived: sum of 3 quarters · filed 2026-02-11 | $18.02M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $4.96M 10-Q · filed 2025-05-08 | $9.62M derived: sum of 2 quarters · filed 2026-02-11 | $14.08M derived: sum of 3 quarters · filed 2026-02-11 | $14.08M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $4.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $9.12M derived: sum of 2 quarters · filed 2026-02-11 | $9.12M derived: sum of 3 quarters · filed 2026-02-11 | $43.88M 10-K · filed 2026-02-11 |
| 2023-09-30 | $4.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.46M derived: sum of 2 quarters · filed 2024-11-06 | $39.23M 10-Q · filed 2024-11-06 | $39.23M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $34.77M 10-Q · filed 2024-08-08 | $34.77M derived: sum of 3 quarters · filed 2025-02-12 | $34.77M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $34.77M 10-Q · filed 2024-05-09 | $34.77M derived: sum of 2 quarters · filed 2025-02-12 | $34.77M derived: sum of 3 quarters · filed 2025-02-12 | $34.77M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $0.00 10-K · filed 2025-02-12 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-02-15 | $0.00 derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-15 | $0.00 derived: sum of 3 quarters · filed 2024-02-15 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $0.00 derived: sum of 2 quarters · filed 2024-02-15 | $523.00K 10-K · filed 2024-02-15 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $523.00K 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $523.00K 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $0.00 derived: sum of 2 quarters · filed 2023-02-15 | $15.08M 10-K · filed 2023-02-15 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $15.08M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $15.08M 10-Q · filed 2021-08-11 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $0.00 derived: sum of 2 quarters · filed 2022-02-15 | $0.00 10-K · filed 2022-02-15 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |